GALT vs. DSGN, PRLD, MACK, GBIO, OGI, RIGL, GTHX, ZVRA, FHTX, and IMMP
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Design Therapeutics (DSGN), Prelude Therapeutics (PRLD), Merrimack Pharmaceuticals (MACK), Generation Bio (GBIO), Organigram (OGI), Rigel Pharmaceuticals (RIGL), G1 Therapeutics (GTHX), Zevra Therapeutics (ZVRA), Foghorn Therapeutics (FHTX), and Immutep (IMMP). These companies are all part of the "pharmaceutical preparations" industry.
Design Therapeutics (NASDAQ:DSGN) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.
In the previous week, Galectin Therapeutics had 7 more articles in the media than Design Therapeutics. MarketBeat recorded 8 mentions for Galectin Therapeutics and 1 mentions for Design Therapeutics. Galectin Therapeutics' average media sentiment score of 0.38 beat Design Therapeutics' score of 0.37 indicating that Design Therapeutics is being referred to more favorably in the media.
Design Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Design Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 49.05%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 209.86%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Design Therapeutics.
Galectin Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.
Galectin Therapeutics received 336 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 60.31% of users gave Galectin Therapeutics an outperform vote while only 32.14% of users gave Design Therapeutics an outperform vote.
Design Therapeutics' return on equity of 0.00% beat Galectin Therapeutics' return on equity.
56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 25.7% of Design Therapeutics shares are held by company insiders. Comparatively, 52.7% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Galectin Therapeutics beats Design Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
